



Hemophilia A

Doctor Discussion Guide

Get the most out of your visit

Talking to your doctor about treatment options should be simple. Use this guide to help you have a productive conversation about AFSTYLA with your healthcare provider. Print this, complete the following checklist, then chat with your doctor.

About me (check or fill all that apply and share with your doctor):

I am currently...

___ on prophylaxis therapy as my regular therapy.

___ using on-demand treatment as my regular therapy.

I currently dose _____ times a week.

I have had _____ bleed(s) in the past 12 months.

About my treatment

Bring the following questions to your doctor’s office to have a meaningful and productive conversation about your treatment.

1. Would I benefit from switching to a new Factor VIII therapy?

2. How does a longer half-life affect the dosing of Factor VIII therapy?

Please see Important Safety Information on page 3 and full prescribing information, including patient product information, at AFSTYLA.com.



About my treatment (cont.)

3. Is twice-weekly dosing an appropriate option for me?

4. What makes AFSTYLA different from my current Factor VIII?

5. What makes AFSTYLA different from other twice-weekly products?

6. What are the potential risks and side effects of AFSTYLA?

7. Can I try AFSTYLA before switching therapies?

Have questions about AFSTYLA?

Call My SourceSM
1-800-676-4266
Mon-Fri, 8 AM to 8 PM ET



Please see Important Safety Information on page 3 and full prescribing information, including patient product information, at AFSTYLA.com.



Important Safety Information

AFSTYLA is used to treat and control bleeding episodes in people with hemophilia A. Used regularly (prophylaxis), AFSTYLA can reduce the number of bleeding episodes and the risk of joint damage due to bleeding. Your doctor might also give you AFSTYLA before surgical procedures.

AFSTYLA is administered by intravenous injection into the bloodstream, and can be self-administered or administered by a caregiver. Your healthcare provider or hemophilia treatment center will instruct you on how to do an infusion. Carefully follow prescriber instructions regarding dose and infusion schedule, which are based on your weight and the severity of your condition.

Do not use AFSTYLA if you know you are allergic to any of its ingredients, or to hamster proteins. Tell your healthcare provider if you previously had an allergic reaction to any product containing Factor VIII (FVIII), or have been told you have inhibitors to FVIII, as AFSTYLA might not work for you. Inform your healthcare provider of all medical conditions and problems you have, as well as all medications you are taking.

Immediately stop treatment and contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.

Your body can make antibodies, called inhibitors, against FVIII, which could stop AFSTYLA from working properly. You might need to be tested for inhibitors from time to time. Contact your healthcare provider if bleeding does not stop after taking AFSTYLA.

In clinical trials, dizziness and allergic reactions were the most common side effects. However, these are not the only side effects possible. Tell your healthcare provider about any side effect that bothers you or does not go away.

Please see full prescribing information for AFSTYLA, including patient product information, at AFSTYLA.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

AFSTYLA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. AFSTYLA® is a registered trademark of CSL Behring Recombinant Facility AG. Biotherapies for Life® is a registered trademark and My SourceSM is a service mark of CSL Behring LLC.

© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. US-AFS-0003 3/2017